Shionogi has a total of 6944 patents globally, out of which 3401 have been granted. Of these 6944 patents, more than 29% patents are active. Japan is where Shionogi has filed the maximum number of patents, followed by United States of America and European Countries. Parallelly, Japan seems to be the main focused R&D centre of Shionogi.
Shionogi was founded in the year 1878 by Gisaburo Shiono. Company is a Japanese pharmaceutical company best known for developing Crestor. As of March 2023, Shionogi has a market cap of $13.70 Billion.
Do read about some of the most popular patents of Shionogi which have been covered by us in this article and also you can find Shionogi patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Shionogi patent portfolio.
How many patents does the founder and the CEO of Shionogi have?
The founder, Gisaburo Shiono, has 0 patents. The CEO, Isao Teshirogi, has 0 patents.
How many patents does Shionogi have?
Shionogi has a total of 6944 patents globally. These patents belong to 1995 unique patent families. Out of 6944 patents, 2029 patents are active.
How Many Patents did Shionogi File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Shionogi Applications Filed | Shionogi Patents Granted |
| 2022 | 56 | 103 |
| 2021 | 109 | 148 |
| 2020 | 164 | 100 |
| 2019 | 191 | 127 |
| 2018 | 150 | 128 |
| 2017 | 219 | 164 |
| 2016 | 230 | 176 |
| 2015 | 248 | 182 |
| 2014 | 169 | 224 |
| 2013 | 225 | 228 |
| 2012 | 310 | 212 |
| 2011 | 315 | 170 |
Which Shionogi Drug Patents are Expiring in the Next 10 Years?
The patent no. US9427402B2 which is expiring in Sep, 2031, describes to create a solubility-enhancing formulation for a poorly soluble drug by combining an alkali agent to create an alkaline environment. Prepare a granulated substance containing the drug, a pH adjuster (alkaline or acidic), and a surfactant to improve oral absorption.
Given below is the list of few drugs patented by Shionogi accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Mulpleta | US9427402B2 | Preparation For Improving Solubility… | Sep, 2031 |
| Ulesfia | US7294342B2 | Ectoparasite Asphyxiator Compositions… | May, 2024 |
| Fetroja | US9238657B2 | Cephalosporin Having Catechol Group | Nov, 2033 |
Interested in knowing about Shionogi’s Drug Patents Expiring in the next 10 years?
How many Shionogi patents are Alive/Dead?
How Many Patents did Shionogi File in Different Countries?
Countries in which Shionogi Filed Patents
| Country | Patents |
| Japan | 1293 |
| United States Of America | 735 |
| Europe | 555 |
| China | 481 |
| Australia | 289 |
| Taiwan | 284 |
| Korea (South) | 260 |
| Germany | 226 |
| Canada | 186 |
| India | 170 |
| Mexico | 150 |
| Spain | 147 |
| Brazil | 131 |
| Russia | 110 |
| Austria | 96 |
| Singapore | 87 |
| Hong Kong (S.A.R.) | 73 |
| Norway | 70 |
| Denmark | 68 |
| Israel | 67 |
| Poland | 67 |
| Portugal | 63 |
| Indonesia | 59 |
| South Africa | 57 |
| Hungary | 52 |
| New Zealand | 39 |
| Slovenia | 37 |
| Argentina | 37 |
| Philippines | 31 |
| Chile | 28 |
Where are Research Centres of Shionogi Patents Located?
10 Best Shionogi Patents
US20040229909A1 is the most popular patent in the Shionogi portfolio. It has received 132 citations so far from companies like IRM, Merck & Co, and Avexa Limited.
Below is the list of 10 most cited patents of Shionogi:
| Publication Number | Citation Count |
| US20040229909A1 | 132 |
| WO2006030807A1 | 129 |
| WO2010110409A1 | 122 |
| WO2011071109A1 | 120 |
| WO2002059099A1 | 119 |
| US6506787B2 | 117 |
| WO2010011812A1 | 116 |
| WO2002053543A1 | 114 |
| WO2007058346A1 | 109 |
| WO2002059100A1 | 109 |
Which Companies are using Shionogi Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Shionogi patent portfolio are Albireo, Viiv Healthcare Company, and Roche Holding.
List of the top forward citing Companies –
| Company | Number of Patents |
| Albireo | 8 |
| Viiv Healthcare Company | 7 |
| Roche Holding Ag | 5 |
| TCD Royalty Sub | 4 |
| Vertex Pharmaceuticals | 3 |
| Oy Granula | 3 |
| Edgemont Pharmaceuticals Llc Liquidating Trust | 3 |
| Galenica | 3 |
| Glaxosmithkline | 3 |
| Concert Pharmaceuticals | 2 |
Count of 102 and 103 Type Rejections based on Shionogi Patents
Top Shionogi Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US20030124088A1 | 14 |
| US8691991B2 | 8 |
| US8129385B2 | 6 |
| US8715727B2 | 6 |
| US8624023B2 | 5 |
| US6730320B2 | 5 |
| US9125803B2 | 5 |
| US8277844B2 | 4 |
| US20080260823A1 | 4 |
| US7582677B2 | 4 |
| US10246478B2 | 4 |
| US8703785B2 | 3 |
| US20050142187A1 | 3 |
| US20080241917A1 | 3 |
| US8642079B2 | 3 |